[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Nucleic Acid-based Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

February 2023 | 102 pages | ID: GABD17B51186EN
GlobalInfoResearch

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The Nucleic Acid-based Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Nucleic Acid-based Drugs market size will reach USD million in 2029, growing at a CAGR of % over the analysis period.

Market segmentation

Nucleic Acid-based Drugs market is split by Type and by Application. For the period 2023-2029, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
  • ASO
  • mRNA
  • siRNA
  • miRNA
  • saRNA
  • Aptamer
Market segment by Application, can be divided into
  • Genetic Disease
  • Cancer
  • Cardiovascular Diseases
  • Other
Market segment by players, this report covers
  • Ionis Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • BioNTech
  • Moderna Therapeutics
  • CureVac
  • Alnylam Pharmaceuticals
  • Regulus Therapeutics
  • Miragen Therapeutics
  • Mina Therapeutics
  • NeXstar Pharmaceuticals
Market segment by regions, regional analysis covers
  • North America
  • Europe
  • Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)
  • South America
  • Middle East & Africa
The content of the study subjects, includes a total of 8 chapters:

Chapter 1, to describe Nucleic Acid-based Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Nucleic Acid-based Drugs, with recent developments and future plans

Chapter 3, the Nucleic Acid-based Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4, to break the market size data at the region level, with key companies in the key region and Nucleic Acid-based Drugs market forecast, by regions, with revenue, from 2023 to 2029.

Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2023 to 2029.

Chapter 7 and 8, to describe Nucleic Acid-based Drugs research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW

1.1 Product Overview and Scope of Nucleic Acid-based Drugs
1.2 Classification of Nucleic Acid-based Drugs by Type
  1.2.1 Overview: Global Nucleic Acid-based Drugs Market Size by Type: 2022 Versus 2028
  1.2.2 Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2029
  1.2.3 ASO
  1.2.4 mRNA
  1.2.5 siRNA
  1.2.6 miRNA
  1.2.7 saRNA
  1.2.8 Aptamer
1.3 Global Nucleic Acid-based Drugs Market by Application
  1.3.1 Overview: Global Nucleic Acid-based Drugs Market Size by Application: 2023 Versus 2029
  1.3.2 Genetic Disease
  1.3.3 Cancer
  1.3.4 Cardiovascular Diseases
  1.3.5 Other
1.4 Global Nucleic Acid-based Drugs Market Size & Forecast
1.5 Market Drivers, Restraints and Trends
  1.5.1 Nucleic Acid-based Drugs Market Drivers
  1.5.2 Nucleic Acid-based Drugs Market Restraints
  1.5.3 Nucleic Acid-based Drugs Trends Analysis

2 COMPANY PROFILES

2.1 Ionis Pharmaceuticals
  2.1.1 Ionis Pharmaceuticals Details
  2.1.2 Ionis Pharmaceuticals Major Business
  2.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
  2.1.4 Ionis Pharmaceuticals Recent Developments and Future Plans
2.2 Sarepta Therapeutics
  2.2.1 Sarepta Therapeutics Details
  2.2.2 Sarepta Therapeutics Major Business
  2.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions
  2.2.4 Sarepta Therapeutics Recent Developments and Future Plans
2.3 Nippon Shinyaku
  2.3.1 Nippon Shinyaku Details
  2.3.2 Nippon Shinyaku Major Business
  2.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions
  2.3.4 Nippon Shinyaku Recent Developments and Future Plans
2.4 BioNTech
  2.4.1 BioNTech Details
  2.4.2 BioNTech Major Business
  2.4.3 BioNTech Nucleic Acid-based Drugs Product and Solutions
  2.4.4 BioNTech Recent Developments and Future Plans
2.5 Moderna Therapeutics
  2.5.1 Moderna Therapeutics Details
  2.5.2 Moderna Therapeutics Major Business
  2.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions
  2.5.4 Moderna Therapeutics Recent Developments and Future Plans
2.6 CureVac
  2.6.1 CureVac Details
  2.6.2 CureVac Major Business
  2.6.3 CureVac Nucleic Acid-based Drugs Product and Solutions
  2.6.4 CureVac Recent Developments and Future Plans
2.7 Alnylam Pharmaceuticals
  2.7.1 Alnylam Pharmaceuticals Details
  2.7.2 Alnylam Pharmaceuticals Major Business
  2.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
  2.7.4 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.8 Regulus Therapeutics
  2.8.1 Regulus Therapeutics Details
  2.8.2 Regulus Therapeutics Major Business
  2.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions
  2.8.4 Regulus Therapeutics Recent Developments and Future Plans
2.9 Miragen Therapeutics
  2.9.1 Miragen Therapeutics Details
  2.9.2 Miragen Therapeutics Major Business
  2.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions
  2.9.4 Miragen Therapeutics Recent Developments and Future Plans
2.10 Mina Therapeutics
  2.10.1 Mina Therapeutics Details
  2.10.2 Mina Therapeutics Major Business
  2.10.3 Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions
  2.10.4 Mina Therapeutics Recent Developments and Future Plans
2.11 NeXstar Pharmaceuticals
  2.11.1 NeXstar Pharmaceuticals Details
  2.11.2 NeXstar Pharmaceuticals Major Business
  2.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
  2.11.4 NeXstar Pharmaceuticals Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Nucleic Acid-based Drugs Revenue and Share by Players (2023 & 2029)
3.2 Nucleic Acid-based Drugs Players Head Office, Products and Services Provided
3.3 Nucleic Acid-based Drugs Mergers & Acquisitions
3.4 Nucleic Acid-based Drugs New Entrants and Expansion Plans

4 GLOBAL NUCLEIC ACID-BASED DRUGS FORECAST BY REGION

4.1 Global Nucleic Acid-based Drugs Market Size by Region: 2023 VS 2029
4.2 Global Nucleic Acid-based Drugs Market Size by Region, (2023-2029)
4.3 North America
  4.3.1 Key Companies of Nucleic Acid-based Drugs in North America
  4.3.2 Current Situation and Forecast of Nucleic Acid-based Drugs in North America
  4.3.3 North America Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)
4.4 Europe
  4.4.1 Key Companies of Nucleic Acid-based Drugs in Europe
  4.4.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Europe
  4.4.3 Europe Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)
4.5 Asia-Pacific
  4.5.1 Key Companies of Nucleic Acid-based Drugs in Asia-Pacific
  4.5.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Asia-Pacific
  4.5.3 Asia-Pacific Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)
  4.5.4 China
  4.5.5 Japan
  4.5.6 South Korea
4.6 South America
  4.6.1 Key Companies of Nucleic Acid-based Drugs in South America
  4.6.2 Current Situation and Forecast of Nucleic Acid-based Drugs in South America
  4.6.3 South America Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)
4.7 Middle East & Africa
  4.7.1 Key Companies of Nucleic Acid-based Drugs in Middle East & Africa
  4.7.2 Current Situation and Forecast of Nucleic Acid-based Drugs in Middle East & Africa
  4.7.3 Middle East & Africa Nucleic Acid-based Drugs Market Size and Prospect (2023-2029)

5 MARKET SIZE SEGMENT BY TYPE

5.1 Global Nucleic Acid-based Drugs Market Forecast by Type (2023-2029)
5.2 Global Nucleic Acid-based Drugs Market Share Forecast by Type (2023-2029)

6 MARKET SIZE SEGMENT BY APPLICATION

6.1 Global Nucleic Acid-based Drugs Market Forecast by Application (2023-2029)
6.2 Global Nucleic Acid-based Drugs Market Share Forecast by Application (2023-2029)

7 RESEARCH FINDINGS AND CONCLUSION

8 APPENDIX

8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer

LIST OF TABLES

Table 1. Global Nucleic Acid-based Drugs Revenue by Type, (USD Million), 2023 VS 2029
Table 2. Global Nucleic Acid-based Drugs Revenue by Application, (USD Million), 2023 VS 2029
Table 3. Ionis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 4. Ionis Pharmaceuticals Major Business
Table 5. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
Table 6. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Sarepta Therapeutics Major Business
Table 8. Sarepta Therapeutics Nucleic Acid-based Drugs Product and Solutions
Table 9. Nippon Shinyaku Corporate Information, Head Office, and Major Competitors
Table 10. Nippon Shinyaku Major Business
Table 11. Nippon Shinyaku Nucleic Acid-based Drugs Product and Solutions
Table 12. BioNTech Corporate Information, Head Office, and Major Competitors
Table 13. BioNTech Major Business
Table 14. BioNTech Nucleic Acid-based Drugs Product and Solutions
Table 15. Moderna Therapeutics Corporate Information, Head Office, and Major Competitors
Table 16. Moderna Therapeutics Major Business
Table 17. Moderna Therapeutics Nucleic Acid-based Drugs Product and Solutions
Table 18. CureVac Corporate Information, Head Office, and Major Competitors
Table 19. CureVac Major Business
Table 20. CureVac Nucleic Acid-based Drugs Product and Solutions
Table 21. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 22. Alnylam Pharmaceuticals Major Business
Table 23. Alnylam Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
Table 24. Regulus Therapeutics Corporate Information, Head Office, and Major Competitors
Table 25. Regulus Therapeutics Major Business
Table 26. Regulus Therapeutics Nucleic Acid-based Drugs Product and Solutions
Table 27. Miragen Therapeutics Corporate Information, Head Office, and Major Competitors
Table 28. Miragen Therapeutics Major Business
Table 29. Miragen Therapeutics Nucleic Acid-based Drugs Product and Solutions
Table 30. Mina Therapeutics Corporate Information, Head Office, and Major Competitors
Table 31. Mina Therapeutics Major Business
Table 32. Mina Therapeutics Nucleic Acid-based Drugs Product and Solutions
Table 33. NeXstar Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 34. NeXstar Pharmaceuticals Major Business
Table 35. NeXstar Pharmaceuticals Nucleic Acid-based Drugs Product and Solutions
Table 36. Global Nucleic Acid-based Drugs Revenue (USD Million) by Players (2023 & 2029)
Table 37. Global Nucleic Acid-based Drugs Revenue Share by Players (2023 & 2029)
Table 38. Nucleic Acid-based Drugs Players Head Office, Products and Services Provided
Table 39. Nucleic Acid-based Drugs Mergers & Acquisitions in the Past Five Years
Table 40. Nucleic Acid-based Drugs New Entrants and Expansion Plans
Table 41. Global Market Nucleic Acid-based Drugs Revenue (USD Million) Comparison by Region (2023 VS 2029)
Table 42. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2023-2029)
Table 43. Key Companies of Nucleic Acid-based Drugs in North America
Table 44. Current Situation and Forecast of Nucleic Acid-based Drugs in North America
Table 45. Key Companies of Nucleic Acid-based Drugs in Europe
Table 46. Current Situation and Forecast of Nucleic Acid-based Drugs in Europe
Table 47. Key Companies of Nucleic Acid-based Drugs in Asia-Pacific
Table 48. Current Situation and Forecast of Nucleic Acid-based Drugs in Asia-Pacific
Table 49. Key Companies of Nucleic Acid-based Drugs in China
Table 50. Key Companies of Nucleic Acid-based Drugs in Japan
Table 51. Key Companies of Nucleic Acid-based Drugs in South Korea
Table 52. Key Companies of Nucleic Acid-based Drugs in South America
Table 53. Current Situation and Forecast of Nucleic Acid-based Drugs in South America
Table 54. Key Companies of Nucleic Acid-based Drugs in Middle East & Africa
Table 55. Current Situation and Forecast of Nucleic Acid-based Drugs in Middle East & Africa
Table 56. Global Nucleic Acid-based Drugs Revenue Forecast by Type (2023-2029)
Table 57. Global Nucleic Acid-based Drugs Revenue Forecast by Application (2023-2029)

LIST OF FIGURES

Figure 1. Nucleic Acid-based Drugs Picture
Figure 2. Global Nucleic Acid-based Drugs Revenue Market Share by Type in 2029
Figure 3. ASO
Figure 4. mRNA
Figure 5. siRNA
Figure 6. miRNA
Figure 7. saRNA
Figure 8. Aptamer
Figure 9. Nucleic Acid-based Drugs Revenue Market Share by Application in 2029
Figure 10. Genetic Disease Picture
Figure 11. Cancer Picture
Figure 12. Cardiovascular Diseases Picture
Figure 13. Other Picture
Figure 14. Global Nucleic Acid-based Drugs Market Size, (USD Million): 2023 VS 2029
Figure 15. Global Nucleic Acid-based Drugs Revenue and Forecast (2023-2029) & (USD Million)
Figure 16. Nucleic Acid-based Drugs Market Drivers
Figure 17. Nucleic Acid-based Drugs Market Restraints
Figure 18. Nucleic Acid-based Drugs Market Trends
Figure 19. Ionis Pharmaceuticals Recent Developments and Future Plans
Figure 20. Sarepta Therapeutics Recent Developments and Future Plans
Figure 21. Nippon Shinyaku Recent Developments and Future Plans
Figure 22. BioNTech Recent Developments and Future Plans
Figure 23. Moderna Therapeutics Recent Developments and Future Plans
Figure 24. CureVac Recent Developments and Future Plans
Figure 25. Alnylam Pharmaceuticals Recent Developments and Future Plans
Figure 26. Regulus Therapeutics Recent Developments and Future Plans
Figure 27. Miragen Therapeutics Recent Developments and Future Plans
Figure 28. Mina Therapeutics Recent Developments and Future Plans
Figure 29. NeXstar Pharmaceuticals Recent Developments and Future Plans
Figure 30. Global Nucleic Acid-based Drugs Revenue Market Share by Region (2023-2029)
Figure 31. Global Nucleic Acid-based Drugs Revenue Market Share by Region in 2029
Figure 32. North America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)
Figure 33. Europe Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)
Figure 34. Asia-Pacific Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)
Figure 35. South America Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)
Figure 36. Middle East & Africa Nucleic Acid-based Drugs Revenue (USD Million) and Growth Rate (2023-2029)
Figure 37. Global Nucleic Acid-based Drugs Market Share Forecast by Type (2023-2029)
Figure 38. Global Nucleic Acid-based Drugs Market Share Forecast by Application (2023-2029)
Figure 39. Methodology
Figure 40. Research Process and Data Source


More Publications